Search results for: "johnson johnson" (218 records) FDA warns Johnson & Johnson over ceftobiprole studies The US Food and Drug Administration (FDA) has sent a warning letter to Johnson & Johnson relating to two clinical trials for ceftobiprole for the treatment of complicated skin... US FDA approves Invega Sustenna injectable formulation using Elan NanoCrystal technology The US Food and Drug Administration has approved Janssen Pharmaceuticals" Invega Sustenna, the first monthly antipsychotic injection, for use with Elan Drug... Catalyst for change With growing environmental pressure to cut hazardous waste and solvent use, searching for greener and more efficient catalysts is a major quest. Dr Sarah Houlton reviews some... Johnson & Johnson and Elan to collaborate on Alzheimer's research Johnson & Johnson (J&J) is to take an 18.4% stake in Irish pharmaceutical company Elan Corporation to acquire the assets and rights to its Alzheimer\'s Immunotherapy Program... Global downturn reduces Johnson Matthey's profit, but fine chemicals & catalysts grow Johnson Matthey reported good sales growth at its Fine Chemicals & Catalysts division for the year ended 31 March 2009. Revenue increased by 16% to Johnson & Johnson to acquire Cougar Biotechnology Johnson & Johnson has agreed to buy Cougar Biotechnology, a biopharmaceutical company focused on oncology, for US$970m ( Chiral centres in molecules Dr Sarah Houlton outlines some of the methods that companies are using today to introduce chiral centres into molecules Johnson & Johnson cuts 154 production posts in Belgium US group Johnson & Johnson has decided to scrap 154 positions at its Belgian subsidiary, Janssen Pharmaceutica, following the reorganisation of its pharmaceutical production... Lonza and Crucell in cell culture medium marketing partnership Lonza has agreed to manufacture, market and sell a cell culture medium developed by Crucell. BioWisdom unveils new partner in safety intelligence programme Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) has become the second partner in BioWisdom\'s Safety Intelligence Program (SIP). The first partner was... New line of metathesis catalysts Johnson Matthey has strengthened its position in the homogeneous catalysis market with a new line of metathesis catalysts. Johnson & Johnson pushes into insulin delivery market Johnson & Johnson (New Brunswick, New Jersey, US) has completed its previously announced acquisition of Animas Corporation (West Chester, Pennsylvania, US), a maker of insulin... Johnson Matthey buys Davy Process Technology Johnson Matthey has purchased developer of chemical process technologies, Davy Process Technology (DPT), from Yukos International UK for Johnson & Johnson moves closer to Guidant deal Johnson & Johnson has agreed a deal to acquire Guidant for $23.2bn in fully diluted equity value.... Johnson Matthey appoints chairman designate Sir John Banham has agreed to join the board of Johnson Matthey as chairman designate with effect from 1 January 2006. It is intended that Banham will be appointed as chairman... Infinity forms alliance with Johnson & Johnson Cancer drug discovery company Infinity Pharmaceuticals has entered into a collaborative agreement enabling Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a... Previous1…8910111213 (current)14Next
